Softgel

Catalent to assess resveratrol formulation across softgel platforms

11-Jan-2017 By Dan Stanton

Catalent will assess Jupiter Orphan Therapeutics’ resveratrol across its softgel technologies in an effort to improve the bioavailability of the rare disease candidate.

Catalent: Limited production begins at suspended French softgel plant

04-Apr-2016 By Dan Stanton

Catalent has missed its forecast for bringing a suspended softgel facility back online, but says production of essential drugs has begun at the French plant.

DISPATCHES FROM CPhI

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

23-Oct-2013 By Dan Stanton

Catalent has announced two new softgel solutions as it adds greater versatility to its Advanced Technologies Business Unit.

Catalent's Brazilian acquisition supports global softgel strategy

10-Oct-2013 By Dan Stanton

Catalent has continued its softgel expansion in emerging markets with the acquisition of Relthy Laboratórios in Brazil.

Catalent Focuses on Softgel in One of Two Chinese Ventures

13-Mar-2013 By Dan Stanton

Catalent says it has acquired a Chinese softgel producer to expand its drug delivery offerings and expects more investments to come as part of a two-pronged plan into China.

Banner tackles Japanese market

20-May-2004

Banner Pharmacaps has entered into an agreement to introduce its
non-animal-derived softgel capsules in Japan for pharmaceutical and
nutritional applications.

Controlled-release - from a softgel

21-Jul-2003

US company Banner Pharmacaps has unveiled what it claims is the
first controlled drug delivery system to be based on a softgel
capsule platform.